At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
Telatinib +1 moredrug
Likely dose
Telatinib 900mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study Evaluating Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
In Brief
A Phase 2 clinical trial evaluating Telatinib and Keytruda for Gastric Cancer and Hepatocellular Carcinoma. Completed, enrolled 16 participants across 3 sites.
Detailed Summary
This is a phase II, single arm, open-label study of two parallel cohorts (advanced stomach and gastroesophageal junction cancer and hepatocellular carcinoma), evaluating the effects of telatinib in combination with Keytruda on progression-free survival.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer, Hepatocellular Carcinoma
CountriesUnited States
CollaboratorsEOC Pharma
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedMar 2021
Enrollment StartJul 2021
Primary CompletionFeb 2024
Study CompletionOct 2025
TodayJul 2026
First PostedMar 15, 2021
Enrollment StartJul 28, 2021
Primary CompletionFeb 14, 2024
Study CompletionOct 20, 2025
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 5.3 years ago
Interventions
Telatinibdrug
900mg by mouth twice daily until disease progression, intolerable toxicities, or withdrawal of consent
Keytrudadrug
200mg intravenous infusion every three weeks until disease progression, intolerable toxicities, or withdrawal of consent